{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:51:21Z","timestamp":1793893881152,"version":"4.8.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,1,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients \u2265 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.18.00400","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T20:59:46Z","timestamp":1543352386000},"page":"144-152","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":220,"title":["Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts"],"prefix":"10.1200","volume":"37","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre de Recherche en Canc\u00e9rologie de Lyon INSERM 1052, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre de Recherche en Canc\u00e9rologie de Lyon INSERM 1052, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre de Recherche en Canc\u00e9rologie de Lyon INSERM 1052, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre de Recherche en Canc\u00e9rologie de Lyon INSERM 1052, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre de Recherche en Canc\u00e9rologie de Lyon INSERM 1052, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"B2","author":"Teras LR","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385991-4.00001-5"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002197"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx189"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1202-y"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12403"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70282-7"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5083"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4474"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8643"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24492"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003743460"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx119"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177204"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30795"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf198"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187773"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24401"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.18.00400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:11:04Z","timestamp":1653811864000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.00400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,10]]}},"alternative-id":["10.1200\/JCO.18.00400"],"URL":"https:\/\/doi.org\/10.1200\/jco.18.00400","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"2018-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}